HCRN: PH2 - Open label, Pacritinib in R/R T-Cell Lymphomas - Clinical Trial
¿Cuál es el Propósito de este estudio?
We are doing this study to find out if an experimental drug called pacritinib (the study drug) is a safe and effective treatment for people with T-cell lymphoproliferative cancers. We want to know how well it works for patients diagnosed with peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma (CTCL).
T-Cell Lymphomas
¿Quién puede participar en el Estudio?
Adults ages 18+ diagnosed with PTCL or CTCL that has relapsed or failed to respond to treatment.
For more information about who can join this study, please contact the study team at terri.lucas@duke.edu.
¿Qué Implica?
Si decide unirse a este estudio, pasará por un período de detección para determinar si es elegible. Durante este período de detección, usted:
- Hacer un examen físico
- Have a heart scan (ECG, Echo)
- Realizar extracciones de sangre
- Have bone marrow samples taken (PTCL patients only)
- Have a tissue biopsy (lymph node)
- Have a skin biopsy (CTCL patients only)
- Have imaging (PET/CT)
If you are eligible to continue in the study after screening, you will begin taking the study drug. The study drug is a capsule that you take by mouth, and you will take the study drug every day at the same time. You will take the study drug for as long as the study doctor believes you are receiving a benefit.
Detalles del Estudio
